Amgen basks in EU approval of Bayer/Onyx cancer drug Stivarga

Ryan McBride

The European Commission has stamped an on (a.k.a. regorafenib) for aggressive cases of colorectal , marking a regulatory victory for Bayer Healthcare and Onyx Pharmaceuticals ($ ONXX). ($ AMGN) benefits, too.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS